Safety, Pharmacokinetics, and Mosquito‐Lethal Effects of Ivermectin in Combination With Dihydroartemisinin‐Piperaquine and Primaquine in Healthy Adult Thai Subjects

Mass administration of antimalarial drugs and ivermectin are being considered as potential accelerators of malaria elimination. The safety, tolerability, pharmacokinetics, and mosquito‐lethal effects of combinations of ivermectin, dihydroartemisinin‐piperaquine, and primaquine were evaluated. Coadmi...

Full description

Saved in:
Bibliographic Details
Published inClinical pharmacology and therapeutics Vol. 107; no. 5; pp. 1221 - 1230
Main Authors Kobylinski, Kevin C., Jittamala, Podjanee, Hanboonkunupakarn, Borimas, Pukrittayakamee, Sasithon, Pantuwatana, Kanchana, Phasomkusolsil, Siriporn, Davidson, Silas A., Winterberg, Markus, Hoglund, Richard M., Mukaka, Mavuto, Pluijm, Rob W., Dondorp, Arjen, Day, Nicholas P.J., White, Nicholas J., Tarning, Joel
Format Journal Article
LanguageEnglish
Published United States 01.05.2020
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Mass administration of antimalarial drugs and ivermectin are being considered as potential accelerators of malaria elimination. The safety, tolerability, pharmacokinetics, and mosquito‐lethal effects of combinations of ivermectin, dihydroartemisinin‐piperaquine, and primaquine were evaluated. Coadministration of ivermectin and dihydroartemisinin‐piperaquine resulted in increased ivermectin concentrations with corresponding increases in mosquito‐lethal effect across all subjects. Exposure to piperaquine was also increased when coadministered with ivermectin, but electrocardiograph QT‐interval prolongation was not increased. One subject had transiently impaired liver function. Ivermectin mosquito‐lethal effect was greater than predicted previously against the major Southeast Asian malaria vectors. Both Anopheles dirus and Anopheles minimus mosquito mortality was increased substantially (20‐fold and 35‐fold increase, respectively) when feeding on volunteer blood after ivermectin administration compared with in vitro ivermectin‐spiked blood. This suggests the presence of ivermectin metabolites that impart mosquito‐lethal effects. Further studies of this combined approach to accelerate malaria elimination are warranted.
AbstractList Mass administration of antimalarial drugs and ivermectin are being considered as potential accelerators of malaria elimination. The safety, tolerability, pharmacokinetics, and mosquito-lethal effects of combinations of ivermectin, dihydroartemisinin-piperaquine, and primaquine were evaluated. Coadministration of ivermectin and dihydroartemisinin-piperaquine resulted in increased ivermectin concentrations with corresponding increases in mosquito-lethal effect across all subjects. Exposure to piperaquine was also increased when coadministered with ivermectin, but electrocardiograph QT-interval prolongation was not increased. One subject had transiently impaired liver function. Ivermectin mosquito-lethal effect was greater than predicted previously against the major Southeast Asian malaria vectors. Both Anopheles dirus and Anopheles minimus mosquito mortality was increased substantially (20-fold and 35-fold increase, respectively) when feeding on volunteer blood after ivermectin administration compared with in vitro ivermectin-spiked blood. This suggests the presence of ivermectin metabolites that impart mosquito-lethal effects. Further studies of this combined approach to accelerate malaria elimination are warranted.
Author Davidson, Silas A.
Kobylinski, Kevin C.
White, Nicholas J.
Hoglund, Richard M.
Pukrittayakamee, Sasithon
Winterberg, Markus
Pluijm, Rob W.
Pantuwatana, Kanchana
Hanboonkunupakarn, Borimas
Jittamala, Podjanee
Dondorp, Arjen
Mukaka, Mavuto
Day, Nicholas P.J.
Phasomkusolsil, Siriporn
Tarning, Joel
Author_xml – sequence: 1
  givenname: Kevin C.
  surname: Kobylinski
  fullname: Kobylinski, Kevin C.
  email: kobylinskikevin@yahoo.com
  organization: Walter Reed Army Institute of Research
– sequence: 2
  givenname: Podjanee
  surname: Jittamala
  fullname: Jittamala, Podjanee
  organization: Mahidol University
– sequence: 3
  givenname: Borimas
  surname: Hanboonkunupakarn
  fullname: Hanboonkunupakarn, Borimas
  organization: Mahidol University
– sequence: 4
  givenname: Sasithon
  surname: Pukrittayakamee
  fullname: Pukrittayakamee, Sasithon
  organization: Dusit
– sequence: 5
  givenname: Kanchana
  surname: Pantuwatana
  fullname: Pantuwatana, Kanchana
  organization: Armed Forces Research Institute of Medical Sciences
– sequence: 6
  givenname: Siriporn
  surname: Phasomkusolsil
  fullname: Phasomkusolsil, Siriporn
  organization: Armed Forces Research Institute of Medical Sciences
– sequence: 7
  givenname: Silas A.
  surname: Davidson
  fullname: Davidson, Silas A.
  organization: Walter Reed Army Institute of Research
– sequence: 8
  givenname: Markus
  surname: Winterberg
  fullname: Winterberg, Markus
  organization: University of Oxford
– sequence: 9
  givenname: Richard M.
  surname: Hoglund
  fullname: Hoglund, Richard M.
  organization: University of Oxford
– sequence: 10
  givenname: Mavuto
  surname: Mukaka
  fullname: Mukaka, Mavuto
  organization: University of Oxford
– sequence: 11
  givenname: Rob W.
  surname: Pluijm
  fullname: Pluijm, Rob W.
  organization: University of Oxford
– sequence: 12
  givenname: Arjen
  surname: Dondorp
  fullname: Dondorp, Arjen
  organization: University of Oxford
– sequence: 13
  givenname: Nicholas P.J.
  surname: Day
  fullname: Day, Nicholas P.J.
  organization: University of Oxford
– sequence: 14
  givenname: Nicholas J.
  surname: White
  fullname: White, Nicholas J.
  organization: University of Oxford
– sequence: 15
  givenname: Joel
  surname: Tarning
  fullname: Tarning, Joel
  organization: University of Oxford
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31697848$$D View this record in MEDLINE/PubMed
BookMark eNo9UW1KxDAUDKLo7ip4AskBrCZNm01_yrrqwooLu-LPkqQvNNqmtc0q_ecRPIbn8iS2fsGDYXjDzOPNGO26ygFCx5ScUULCc137MzqlfAeNaMzCgMcs3kUjQkgSJCHjB2jcto89jRIh9tEBozyZikiM0MdaGvDdKV7lsimlrp6sA291e4qly_Bt1T5vra8-396X4HNZ4LkxoH2LK4MXL9CUPbEO9zOrSmWd9LZy-MH6HF_avMuaSjYeSttaZ13vsrI1NLL3dPAdsGps-Ut7jxuQhc87fJFtC483ubR4vVWPQ-Ah2jOyaOHoFyfo_mq-md0Ey7vrxexiGeiIEh4wYWLGk8gwlTAhFQlZAqC1zATnJKbakFhLBWCEUFOWhUJkdKq5MiqLpQzZBJ38-NZbVUKW1sOBTZf-vawXBD-CV1tA97-nJB2qSPsq0qGKdLbaDMi-AJA3g5c
CitedBy_id crossref_primary_10_1186_s12936_023_04685_1
crossref_primary_10_2139_ssrn_3706347
crossref_primary_10_1128_aac_00181_24
crossref_primary_10_1136_bmjopen_2023_072347
crossref_primary_10_1128_aac_01730_22
crossref_primary_10_1186_s13071_021_04675_9
crossref_primary_10_1016_j_jmsacl_2023_12_004
crossref_primary_10_1186_s12936_023_04624_0
crossref_primary_10_1126_scitranslmed_abe1535
crossref_primary_10_1128_aac_01272_23
crossref_primary_10_1021_acs_jmedchem_4c01606
crossref_primary_10_1038_s41467_022_30267_x
crossref_primary_10_2139_ssrn_3636557
crossref_primary_10_1038_s41598_023_34719_2
crossref_primary_10_1002_cpt_3471
crossref_primary_10_7554_eLife_83201
crossref_primary_10_1002_prp2_712
crossref_primary_10_2174_1567201819666220516163242
crossref_primary_10_1371_journal_pntd_0009144
crossref_primary_10_2196_20904
crossref_primary_10_12688_wellcomeopenres_20613_2
crossref_primary_10_12688_wellcomeopenres_20613_1
crossref_primary_10_1016_S1473_3099_24_00580_2
crossref_primary_10_1002_jcph_2073
crossref_primary_10_1038_s41598_024_81743_x
crossref_primary_10_1021_acs_jmedchem_1c00498
crossref_primary_10_1186_s13071_021_04870_8
crossref_primary_10_1186_s13071_022_05557_4
crossref_primary_10_1002_psp4_13233
crossref_primary_10_3390_ph13080196
crossref_primary_10_1128_AAC_00741_20
crossref_primary_10_1111_mve_12788
crossref_primary_10_1016_j_ijid_2024_107236
ContentType Journal Article
Copyright 2019 The Authors. published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.
2019 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.
Copyright_xml – notice: 2019 The Authors. published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.
– notice: 2019 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.
DBID 24P
CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1002/cpt.1716
DatabaseName Wiley Online Library Open Access
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE

Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1532-6535
EndPage 1230
ExternalDocumentID 31697848
CPT1716
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Thailand
GeographicLocations_xml – name: Thailand
GrantInformation_xml – fundername: Bill & Melinda Gates Foundation
  funderid: OPP1134284
– fundername: Wellcome Trust
– fundername: Department for International Development
GroupedDBID ---
--K
-Q-
.55
.GJ
0R~
1B1
1CY
1OB
1OC
24P
29B
33P
354
36B
39C
3O-
4.4
52O
53G
5GY
5RE
6J9
70F
8F7
AAESR
AAHHS
AAHQN
AAIPD
AAKAS
AAMNL
AANHP
AANLZ
AAONW
AAQOH
AAQQT
AAWTL
AAYCA
AAYOK
AAZKR
ABCUV
ABJNI
ABLJU
ABQWH
ACBNA
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACPOU
ACRPL
ACXQS
ACYXJ
ADBBV
ADBTR
ADKYN
ADNMO
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AENEX
AEQDE
AEUYR
AFBPY
AFFNX
AFFPM
AHBTC
AI.
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMYDB
ASPBG
AVWKF
AZFZN
AZVAB
BDRZF
BFHJK
BMXJE
BRXPI
C45
CAG
COF
CS3
DCZOG
DPXWK
DU5
EBS
EE.
EJD
EMOBN
F5P
GODZA
GWYGA
HGLYW
IH2
IHE
J5H
L7B
LATKE
LEEKS
LITHE
LOXES
LSO
LUTES
LYRES
M41
MEWTI
N4W
N9A
NQ-
O9-
OPC
OVD
P2P
P2W
PALCI
RIG
RIWAO
RJQFR
RNTTT
ROL
RPZ
SAMSI
SEW
SJN
SUPJJ
TEORI
TWZ
UHS
VH1
WBKPD
WH7
WOHZO
WXSBR
WYJ
X7M
Y6R
YCJ
YFH
YOC
YXB
ZGI
ZXP
ZZTAW
CGR
CUY
CVF
ECM
EIF
NPM
PKN
ID FETCH-LOGICAL-c4106-38f53694f3b938ab0239eeccad866051cf05cabeef88b73d288d17c6bfbd5aa23
IEDL.DBID 24P
ISSN 0009-9236
IngestDate Wed Feb 19 02:28:28 EST 2025
Wed Jan 22 16:35:49 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
License Attribution-NonCommercial
2019 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4106-38f53694f3b938ab0239eeccad866051cf05cabeef88b73d288d17c6bfbd5aa23
OpenAccessLink https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcpt.1716
PMID 31697848
PageCount 10
ParticipantIDs pubmed_primary_31697848
wiley_primary_10_1002_cpt_1716_CPT1716
PublicationCentury 2000
PublicationDate May 2020
PublicationDateYYYYMMDD 2020-05-01
PublicationDate_xml – month: 05
  year: 2020
  text: May 2020
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Clinical pharmacology and therapeutics
PublicationTitleAlternate Clin Pharmacol Ther
PublicationYear 2020
References 1998; 28
2017; 2
2014; 91
2018; 105
2015; 30
1996; 50
2019; 16
1996
2008; 862
2018; 67
2011; 16
2012; 56
2012; 11
2016; 15
1987; 18
2018; 69
2015; 152
2018; 18
2018; 17
2018; 391
1968; 38
2015; 60
2002; 42
2010; 116
2017; 17
2013; 12
2017; 16
2016; 43
2011; 42
2014; 58
2014; 13
2005; 10
2008; 876
2014
2019; 393
1994; 50
2014; 6
1969; 134
2006; 100
2012; 42
2010; 9
References_xml – volume: 56
  start-page: 1571
  year: 2012
  end-page: 1577
  article-title: Randomized, double‐blind, placebo‐controlled trial of monthly versus bimonthly dihydroartemisinin‐piperaquine chemoprevention in adults at high risk of malaria
  publication-title: Antimicrob. Agents Chemother.
– volume: 42
  start-page: 341
  year: 2011
  end-page: 343
  article-title: A case report of ivermectin‐induced prolonged liver dysfunction in an elderly patient with scabies
  publication-title: Japanese J. Clin. Pharmacol. Therapeut.
– volume: 13
  start-page: e286
  year: 2014
  article-title: The challenge of artemisinin resistance can only be met by eliminating malaria across the Greater Mekong subregion
  publication-title: Malaria J.
– volume: 17
  start-page: e405
  year: 2018
  article-title: The dynamic of asymptomatic infections following mass drug administrations with dihydroarteminisin‐piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos
  publication-title: Malaria J.
– volume: 134
  start-page: 802
  year: 1969
  end-page: 819
  article-title: Gametocytocidal and sporontocidal effects of primaquine upon two strains of
  publication-title: Military Med.
– volume: 862
  start-page: 227
  year: 2008
  end-page: 236
  article-title: Development and validation of a liquid chromatographic‐tandem mass spectrometric method for determination of piperaquine in plasma stable isotope labeled internal standard does not always compensate for matrix effects
  publication-title: J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
– volume: 15
  start-page: e339
  year: 2016
  article-title: Impact of using artemisinin‐based combination therapy (ACT) in the treatment of uncomplicated malaria from in a non‐endemic zone
  publication-title: Malaria J.
– volume: 16
  year: 2019
  article-title: The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: a cluster randomised trial
  publication-title: PLoS Med.
– year: 1996
– volume: 9
  start-page: e373
  year: 2010
  article-title: Malaria transmission and vector behaviour in a forested malaria focus in central Vietnam and the implications for vector control
  publication-title: Malaria J.
– volume: 12
  start-page: e364
  year: 2013
  article-title: Entomological determinants of insecticide‐treated bed net effectiveness in Western Myanmar
  publication-title: Malaria J.
– volume: 91
  start-page: 655
  year: 2014
  end-page: 662
  article-title: Rationale for the coadministration of albendazole and ivermectin to humans for malaria parasite transmission control
  publication-title: Am. J. Trop. Med. Hyg.
– volume: 152
  start-page: 220
  year: 2015
  end-page: 227
  article-title: The relationship between wing length, blood meal volume, and fecundity for seven colonies of species housed at the Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
  publication-title: Acta Tropica
– volume: 43
  start-page: 1030
  year: 2016
  end-page: 1036
  article-title: Effect of high‐fat meal intake on the pharmacokinetic profile of ivermectin in Japanese patients with scabies
  publication-title: J. Dermatol.
– volume: 42
  start-page: 1122
  year: 2002
  end-page: 1133
  article-title: Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects
  publication-title: J. Clin. Pharmacol.
– volume: 6
  start-page: 260ra147
  year: 2014
  article-title: Characterization of an in vivo concentration‐effect relationship for piperaquine in malaria chemoprevention
  publication-title: Science Transl. Med.
– volume: 876
  start-page: 61
  year: 2008
  end-page: 68
  article-title: A liquid chromatographic‐tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma
  publication-title: J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
– year: 2014
– volume: 18
  start-page: 615
  year: 2018
  end-page: 626
  article-title: Safety and mosquitocidal efficacy of high‐dose ivermectin when co‐administered with dihydroartemisinin‐piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double‐blind, placebo‐controlled trial
  publication-title: Lancet Infect. Dis.
– volume: 105
  start-page: 388
  year: 2018
  end-page: 401
  article-title: Pharmacokinetics‐pharmacodynamics of high‐dose ivermectin with dihydroartemisinin‐piperaquine on mosquitocidal activity and QT‐Prolongation (IVERMAL)
  publication-title: Clin. Pharmacol. Ther.
– volume: 69
  start-page: 1112
  year: 2018
  end-page: 1119
  article-title: Human direct skin feeding versus membrane feeding to assess the mosquitocidal efficacy of high‐dose ivermectin (IVERMAL Trial)
  publication-title: Clin. Infect. Dis.
– volume: 13
  start-page: e417
  year: 2014
  article-title: Evaluation of ivermectin mass drug administration for malaria transmission control across different West African environments
  publication-title: Malaria J.
– volume: 100
  start-page: 795
  year: 2006
  end-page: 797
  article-title: First case of ivermectin‐induced severe hepatitis
  publication-title: Trans. Royal Soc. Trop. Med. Hyg.
– volume: 42
  start-page: 1088
  year: 2012
  end-page: 1095
  article-title: metabolism of piperaquine is primarily mediated by CYP3A4
  publication-title: Xenobiotica
– volume: 116
  start-page: 119
  year: 2010
  end-page: 125
  article-title: The effect of oral anthelmintics on the survivorship and re‐feeding frequency of anthropophilic mosquito disease vectors
  publication-title: Acta Tropica
– volume: 10
  start-page: 251
  year: 2005
  end-page: 262
  article-title: Behavioural heterogeneity of species in ecologically different localities in Southeast Asia: a challenge for vector control
  publication-title: Trop. Med. Int. Health
– volume: 67
  start-page: 817
  year: 2018
  end-page: 826
  article-title: A controlled trial of mass drug administration to interrupt transmission of multidrug‐resistant falciparum malaria in Cambodian villages
  publication-title: Clin. Infect. Dis.
– volume: 17
  start-page: e15
  year: 2017
  end-page: e20
  article-title: Does antimalarial mass drug administration increase or decrease the risk of resistance?
  publication-title: Lancet Infect. Dis.
– volume: 11
  start-page: e418
  year: 2012
  article-title: Rationale for recommending a lower dose of primaquine as a gametocytocide in populations where G6PD deficiency is common
  publication-title: Malaria J.
– volume: 38
  start-page: 625
  year: 1968
  end-page: 632
  article-title: Gametocytocidal and sporontocidal effects of primaquine and of sulfadiazine with pyrimethamine in a chloroquine‐resistant strain of
  publication-title: Bull. World Health Organ.
– volume: 28
  start-page: 313
  year: 1998
  end-page: 321
  article-title: Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes
  publication-title: Xenobiotica
– volume: 60
  start-page: 357
  year: 2015
  end-page: 365
  article-title: Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double‐blind, randomized, clinical trial
  publication-title: Clin. Infect. Dis.
– volume: 16
  start-page: e280
  year: 2017
  article-title: Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion
  publication-title: Malaria J.
– volume: 16
  start-page: e474
  year: 2017
  article-title: Ivermectin susceptibility, sporontocidal effect, and inhibition of time to re‐feed in the Amazonian malaria vector
  publication-title: Malaria J.
– volume: 391
  start-page: 1916
  year: 2018
  end-page: 1926
  article-title: Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on malaria in Eastern Myanmar: an observational study of a regional elimination programme
  publication-title: Lancet
– volume: 50
  start-page: 646
  year: 1994
  end-page: 653
  article-title: Prevention of sporogony of and in mosquitoes by transmission‐blocking antimalarials
  publication-title: Am. J. Trop. Med. Hyg.
– volume: 30
  start-page: 385
  year: 2015
  end-page: 390
  article-title: Mechanism for transport of ivermectin to the stratum corneum in rats
  publication-title: Drug Metab. Pharmacokinet.
– volume: 16
  start-page: 608
  year: 2011
  end-page: 621
  article-title: Where would I be without ivermectin? Capturing the benefits of community‐directed treatment with ivermectin in Africa
  publication-title: Trop. Med. Int. Health
– volume: 18
  start-page: 289
  year: 1987
  end-page: 302
  article-title: Comparative and metabolism of ivermectin in steers, sheep, swine, and rat
  publication-title: Drug Metab. Rev.
– volume: 2
  start-page: e81
  year: 2017
  article-title: Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin‐resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar
  publication-title: Wellcome Open Res.
– volume: 15
  start-page: e43
  year: 2016
  article-title: Treatment outcomes in a safety observational study of dihydroartemisinin/piperaquine (Eurartesim®) in the treatment of uncomplicated malaria at public health facilities in four African countries
  publication-title: Malaria J.
– volume: 15
  start-page: e491
  year: 2016
  article-title: Filling gaps on ivermectin knowledge: effects on the survival and reproduction of , a Latin American malaria vector
  publication-title: Malaria J.
– volume: 50
  start-page: 407
  year: 1996
  end-page: 410
  article-title: Ivermectin distribution in the plasma and tissues of patients infected with
  publication-title: Eur. J. Clin. Pharmacol.
– volume: 393
  start-page: 1517
  year: 2019
  end-page: 1526
  article-title: Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster‐randomised trial
  publication-title: Lancet
– volume: 58
  start-page: 7340
  year: 2014
  end-page: 7346
  article-title: Open‐label crossover study of primaquine and dihydroartemisinin‐piperaquine pharmacokinetics in healthy adult Thai subjects
  publication-title: Antimicrob. Agents Chemother.
SSID ssj0004988
Score 2.4852026
Snippet Mass administration of antimalarial drugs and ivermectin are being considered as potential accelerators of malaria elimination. The safety, tolerability,...
SourceID pubmed
wiley
SourceType Index Database
Publisher
StartPage 1221
SubjectTerms Adolescent
Adult
Animals
Anopheles - drug effects
Antimalarials - administration & dosage
Antimalarials - adverse effects
Antimalarials - pharmacokinetics
Artemisinins - administration & dosage
Artemisinins - adverse effects
Artemisinins - pharmacokinetics
Drug Interactions
Drug Therapy, Combination
Female
Humans
Insecticides - administration & dosage
Insecticides - adverse effects
Insecticides - pharmacokinetics
Ivermectin - administration & dosage
Ivermectin - adverse effects
Ivermectin - pharmacokinetics
Malaria - prevention & control
Male
Middle Aged
Primaquine - administration & dosage
Primaquine - adverse effects
Primaquine - pharmacokinetics
Quinolines - administration & dosage
Quinolines - adverse effects
Quinolines - pharmacokinetics
Thailand
Young Adult
Title Safety, Pharmacokinetics, and Mosquito‐Lethal Effects of Ivermectin in Combination With Dihydroartemisinin‐Piperaquine and Primaquine in Healthy Adult Thai Subjects
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcpt.1716
https://www.ncbi.nlm.nih.gov/pubmed/31697848
Volume 107
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NTtwwELYKvXBB0Jb_Vj5UeyIisROvfUS0qy1iUaQuglvkX-0KNbsl4bA3HoHH4Ln6JJ2Jd1mOSFGiJI7taOzxjDXfN4R8ZyGDVb7QSRA6TXCPIVFShoQHaUNfuTxjiEYeXYvhTX55V9wtoyoRCxP5IV433HBmdPoaJ7g2zdmaNNTOMaFuJjbIR0TWIm8-y8s1JlJJucqiBkaMWBHPpuxs9eWbReetYdqtLIMdsr00Cel5lOEu-eDrT6RXRk7pxSkdryFSzSnt0XLNNr34TF5-6-BbKLZ6fA9_Fovq2tHRrPn7CLP239PzlW8n0E7kK27oLNBfMI7_oMarKRygGsBN7iRFb6fthP6YThbuYYZRnzAaMJME1FJO59AdqLP2XQMl0lXEW6gjopoW9BxpPaDnekpBNeFeT_OF3Ax-ji-GyTL9QmLzDCPiZCi4UHngRnGpDcJgPUrcSQFOUGZDWlhtvA9Smj53TEqX9a0wwbhCa8b3yGY9q_0BoQZ0rkqDtSI1uVdcSZM6z1LuLVfW2UOyHyVRzSPHRsUzAf5tLg9JrxPN64tIs8wqEGKFQqwuyjFej95b8JhsMfSZu6DFE7LZPjz6r2BYtOZbN4LgfF2O_gN7ONF3
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NTtwwELYoHNoLKpS20NL6UO2JiMROvLY4IVq0wC6KxKJyi_yrXVVkFzYc9tZH6GPwXH2SzsSE5VgpUpTEsRN9nvHMyPMNId9YyGCVL3QShE4TjDEkSsqQ8CBt6CuXZwyzkUeXYnCdn98UN2vkqMuFifwQzwE3lIxWX6OAY0D6cMUaaudYUTcTr8hGLlgfpZLl5SopUknZlVEDK0Z0zLMpO-zefLHqvLRM26Xl9C3ZfLIJ6XEEcYus-Xqb9MpIKr08oONVjtTigPZouaKbXr4jj1c6-Aaadbd_wa_Fprp2dDRb3D2A2P79_WfomwmMEwmLF3QW6BlM5FtUeTWFA3QD-MktVPTntJnQ79PJ0t3PcNsnTAcsJQG9lNM5fA70Wft2gBL5KuIl9BHTmpb0GHk94Mv1lIJuwmDPYodcn_4YnwySp_oLic0z3BInQ8GFygM3ikttMA_WI-ROCvCCMhvSwmrjfZDS9LljUrqsb4UJxhVaM_6erNez2n8k1IDSVWmwVqQm94oraVLnWcq95co6u0s-RCSqeSTZqHgmwMHN5S7ptdA8P4g8y6wCECsEsTopx3je-9-GX8nrwXg0rIZnlxefyBuGDnS7g_EzWW_uH_w-WBmN-dLOpn_WctPX
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NTtwwELb4kSouVYEC2xbqA9oTEUmceO0jgq6WsosidVG5Rf7VrhDZLRsOe-sj9DH6XDwJM_H-cESKFCVxbEefPZ5xZr4h5DT1CazyuYo8V3GEewyRFMJHzAvjO9JmSYrRyINb3rvLft7n9wuvSoyFCfwQqw03nBmNvMYJPrX-fE0aaqaYUDfhm2S7-deHrM5ZsY6JlEIss6iBEsOXxLNxer58882i81YxbVaW7ifycaES0ouA4S7ZcNUeaReBU3p-RofrEKnZGW3TYs02Pd8n_38p72ootrz9AF8WiqrK0sFk9ucZZu3L3399V4-gncBXPKMTT69hHD-ixKsoHCAawExukKK_x_WIXo1Hc_s0Qa9PGA2YSQJqKcZT6A7UWbmmgQLpKsIl1BGimub0Amk9oOdqTEE04V7P7DO56_4YXvaiRfqFyGQJesQJnzMuM8-0ZEJpDIN1iLgVHIygxPg4N0o754XQHWZTIWzSMVx7bXOlUnZAtqpJ5Y4I1SBzZeyN4bHOnGRS6Ni6NGbOMGmsaZHDgEQ5DRwbJUs42LeZaJF2A83qQaBZTksAsUQQy8tiiOcv7y34nXworrpl__r25ivZSdF8bvwXv5Gt-unZHYOOUeuTZjC9Assv0wk
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety%2C+Pharmacokinetics%2C+and+Mosquito%E2%80%90Lethal+Effects+of+Ivermectin+in+Combination+With+Dihydroartemisinin%E2%80%90Piperaquine+and+Primaquine+in+Healthy+Adult+Thai+Subjects&rft.jtitle=Clinical+pharmacology+and+therapeutics&rft.au=Kobylinski%2C+Kevin+C.&rft.au=Jittamala%2C+Podjanee&rft.au=Hanboonkunupakarn%2C+Borimas&rft.au=Pukrittayakamee%2C+Sasithon&rft.date=2020-05-01&rft.issn=0009-9236&rft.eissn=1532-6535&rft.volume=107&rft.issue=5&rft.spage=1221&rft.epage=1230&rft_id=info:doi/10.1002%2Fcpt.1716&rft.externalDBID=10.1002%252Fcpt.1716&rft.externalDocID=CPT1716
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-9236&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-9236&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-9236&client=summon